ABT
NYSE · Health Care
Abbott Laboratories
$91.05
-1.66 (-1.79%)
Financial Highlights (FY 2026)
Revenue
44.46B
Net Income
6.54B
Gross Margin
56.7%
Profit Margin
14.7%
Rev Growth
+0.5%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 44.46B | 44.23B | 33.22B | 38.26B |
| Gross Profit | 25.19B | 25.06B | 17.29B | 19.91B |
| Operating Income | 8.08B | 7.23B | 7.86B | 10.21B |
| Net Income | 6.54B | 5.86B | 6.02B | 6.40B |
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
| Rev Growth | +0.5% | +0.5% | +10.5% | -2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 16.40B | 16.40B | 25.40B | 31.10B |
| Total Equity | 66.11B | 66.11B | 104.22B | 116.10B |
| D/E Ratio | 0.25 | 0.25 | 0.24 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 9.76B | 9.23B | 10.39B | 11.25B |
| Free Cash Flow | — | — | 6.26B | 6.35B |